Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies. (2nd January 2022)

• Record Type: Journal Article
• Authors: Fang, Chih-Yeu; Liu, Chia-Chyi
• Is Part Of: Expert opinion on drug discovery. Volume 17:Number 1(2022)
• Page Start: 27
• Page End: 39
• Publication Date: 2022-01-02
• Subjects: Hand, foot, and mouth diseases -- enterovirus -- coxsackievirus -- vaccines -- antiviral drugs; 615.1
• DOI: 10.1080/17460441.2021.1965987
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction: Hand, foot, and mouth disease (HFMD) poses a great threat to young children in the Asia-Pacific region. HFMD is usually caused by enterovirus A, and infection with enterovirus A71 (EV-A71) is particularly associated with severe complications. However, coxsackievirus CV-A16, CV-A6, and CV-A10 pandemics have been observed in recent HFMD outbreaks. Inactivated monovalent EV-A71 vaccines are available to prevent EV-A71 infection; however, they cannot prevent infections by non-EV-A71 enteroviruses. Anti-enteroviral drugs are still in the developmental stage. Application of novel strategies will facilitate the development of new therapies against these emerging HFMD-associated enteroviruses. Areas covered: The authors highlight the current approaches for anti-enterovirus therapeutic development and discuss the application of these novel strategies for the discovery of vaccines and antiviral drugs for enteroviruses. Expert opinion: The maturation of DNA/RNA vaccine technology could be applied for rapid and robust development of multivalent enterovirus vaccines. Structure biology and neutralization antibody studies decipher the immunodominant sites of enteroviruses for vaccine design. Nucleotide aptamer library screening is a novel, fast, and cost-effective strategy for the development of antiviral agents. Animal models carrying viral receptors and attachment factors are required for enterovirus study and vaccine/antiviral development. Currently developed antivirals require effectiveness evaluation in clinical trials.